Goldman Sachs’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$107K Buy
154,801
+86,824
+128% +$64.1K ﹤0.01% 6199
2025
Q4
$48.4K Sell
67,977
-159,520
-70% -$217K ﹤0.01% 6291
2025
Q3
$369K Sell
227,497
-52,726
-19% -$53.1K ﹤0.01% 5662
2025
Q2
$171K Buy
280,223
+69,052
+33% +$35.1K ﹤0.01% 5702
2025
Q1
$120K Sell
211,171
-94,837
-31% -$93.6K ﹤0.01% 5749
2024
Q4
$438K Sell
306,008
-9,794
-3% -$22K ﹤0.01% 5324
2024
Q3
$609K Buy
315,802
+95,819
+44% +$271K ﹤0.01% 4942
2024
Q2
$682K Buy
219,983
+137,871
+168% +$569K ﹤0.01% 4657
2024
Q1
$429K Buy
82,112
+7,627
+10% +$36.5K ﹤0.01% 4816
2023
Q4
$241K Sell
74,485
-44,303
-37% -$95.6K ﹤0.01% 5083
2023
Q3
$303K Buy
118,788
+43,517
+58% +$182K ﹤0.01% 4892
2023
Q2
$442K Buy
75,271
+52,974
+238% +$308K ﹤0.01% 4808
2023
Q1
$63.5K Sell
22,297
-18,649
-46% -$52.4K ﹤0.01% 5518
2022
Q4
$82.3K Buy
40,946
+1,423
+4% +$3.47K ﹤0.01% 5519
2022
Q3
$115K Buy
39,523
+20,275
+105% +$94.6K ﹤0.01% 5654
2022
Q2
$108K Sell
19,248
-7,923
-29% -$64.1K ﹤0.01% 5837
2022
Q1
$320K Buy
27,171
+12,870
+90% +$156K ﹤0.01% 5624
2021
Q4
$271K Buy
+14,301
New +$312K ﹤0.01% 5723

Other funds holding TNYA

Goldman Sachs's TNYA Position: Q1 2026 in Review

Goldman Sachs increased its Tenaya Therapeutics (TNYA) stake by 128% in Q1 2026, buying an estimated $64.1K and bringing the position to 154,801 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #6199.

Goldman Sachs first reported a position in TNYA in Q4 2021 and has held it in 18 quarters since. The position peaked at $682K in Q2 2024. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • Goldman Sachs held 154,801 shares of Tenaya Therapeutics worth $107K as of Q1 2026.
  • Goldman Sachs bought 86,824 Tenaya Therapeutics shares in Q1 2026, an estimated $64.1K.
  • Tenaya Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6199 holding.
  • Goldman Sachs first reported a position in Tenaya Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Goldman Sachs's Tenaya Therapeutics position peaked at $682K in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.